LLY

1,062.58

-1.36%↓

JNJ

222.5

+0.39%↑

ABBV

212.21

-0.25%↓

UNH

377.74

-1.21%↓

MRK

115.26

+0.12%↑

LLY

1,062.58

-1.36%↓

JNJ

222.5

+0.39%↑

ABBV

212.21

-0.25%↓

UNH

377.74

-1.21%↓

MRK

115.26

+0.12%↑

LLY

1,062.58

-1.36%↓

JNJ

222.5

+0.39%↑

ABBV

212.21

-0.25%↓

UNH

377.74

-1.21%↓

MRK

115.26

+0.12%↑

LLY

1,062.58

-1.36%↓

JNJ

222.5

+0.39%↑

ABBV

212.21

-0.25%↓

UNH

377.74

-1.21%↓

MRK

115.26

+0.12%↑

LLY

1,062.58

-1.36%↓

JNJ

222.5

+0.39%↑

ABBV

212.21

-0.25%↓

UNH

377.74

-1.21%↓

MRK

115.26

+0.12%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Avatud

SektorTervishoid

2.61 -0.76

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.5300000000000002

Max

2.77

Põhinäitajad
By Trading Economics
Sissetulek	1.2M -31M
Müük	-70K 1.3M
Aktsiakasum	-0.26
Kasumimarginaal	-2,402.848
Töötajad	161
EBITDA	12M -30M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+68.31% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	10. aug 2026

Turustatistika
By TradingEconomics
Turukapital	8.8M 262M
Eelmine avamishind	3.37
Eelmine sulgemishind	2.61

Uudiste sentiment

By Acuity

84%

16%

318 / 344 Pingereas Healthcare

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. juuni 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1. juuni 2026, 23:38 UTC

Omandamised, ülevõtmised, äriostud

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1. juuni 2026, 23:37 UTC

Market Talk

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1. juuni 2026, 23:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. juuni 2026, 23:01 UTC

Market Talk

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1. juuni 2026, 22:08 UTC

Omandamised, ülevõtmised, äriostud

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1. juuni 2026, 22:01 UTC

Omandamised, ülevõtmised, äriostud

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1. juuni 2026, 22:01 UTC

Omandamised, ülevõtmised, äriostud

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1. juuni 2026, 21:55 UTC

Omandamised, ülevõtmised, äriostud

Greg Abel's Week Is Off to Quite a Start -- WSJ

1. juuni 2026, 21:53 UTC

Market Talk

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1. juuni 2026, 21:22 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1. juuni 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

1. juuni 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1. juuni 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

1. juuni 2026, 20:46 UTC

Omandamised, ülevõtmised, äriostud

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1. juuni 2026, 20:22 UTC

Omandamised, ülevõtmised, äriostud

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1. juuni 2026, 20:21 UTC

Omandamised, ülevõtmised, äriostud

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1. juuni 2026, 20:21 UTC

Omandamised, ülevõtmised, äriostud

Array Digital Infrastructure Declares $11 Special Div

1. juuni 2026, 20:20 UTC

Omandamised, ülevõtmised, äriostud

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1. juuni 2026, 19:40 UTC

Market Talk

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1. juuni 2026, 19:28 UTC

Market Talk

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1. juuni 2026, 19:01 UTC

Market Talk

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1. juuni 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1. juuni 2026, 18:54 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1. juuni 2026, 18:33 UTC

Market Talk

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1. juuni 2026, 18:32 UTC

Market Talk

Precious Metals Fall to Start June -- Market Talk

1. juuni 2026, 18:00 UTC

Omandamised, ülevõtmised, äriostud

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1. juuni 2026, 17:18 UTC

Market Talk

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1. juuni 2026, 17:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. juuni 2026, 17:10 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

68.31% tõus

12 kuu keskmine prognoos

Keskmine 4.78 USD 68.31%

Kõrge 7 USD

Madal 2.2 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

318 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.